0 285

Cited 1 times in

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study

DC Field Value Language
dc.contributor.author김현욱-
dc.contributor.author김혜련-
dc.contributor.author이기쁨-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.contributor.author홍민희-
dc.contributor.author안병철-
dc.date.accessioned2023-08-09T06:42:01Z-
dc.date.available2023-08-09T06:42:01Z-
dc.date.issued2023-06-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/195937-
dc.description.abstractIntroduction: Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that provides a high level of selectivity for sensitizing and p.Thr790Met (T790M) EGFR mutations. We aimed to collect real-world data regarding the efficacy and safety of lazertinib. Methods: This study included patients treated with lazertinib for T790M-mutated non-small cell lung cancer who had previously been treated with an EGFR-TKI. The primary outcome measure was progression-free survival (PFS). Additionally, this study evaluated overall survival (OS), time-to-treatment failure (TTF), duration of response (DOR), objective response rate (ORR) and disease control rate (DCR). Drug safety was also assessed. Results: In a study of 103 patients, 90 received lazertinib as a second- or third-line therapy. The ORR and DCR were 62.1% and 94.2%, respectively. The median follow-up duration was 11.1 months, and the median PFS period was 13.9 (95% confidence interval [CI], 11.0-not reached [NR]) months. OS, DOR, and TTF had not yet been determined. In a subgroup of 33 patients with evaluable brain metastases, the intracranial DCR and ORR were 93.5% and 57.6%, respectively. The median intracranial PFS period was 17.1 (95% CI, 13.9-NR) months. Approximately 17.5% of patients had dose modification or discontinuation due to adverse events, with the most common being grade 1 or 2 paresthesia. Conclusions: The efficacy and safety of lazertinib were recapitulated in a real-world study reflecting routine clinical practice in Korea, showing durable disease control both systematically and intracranially, with manageable side effects.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAniline Compounds / therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / genetics-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / pathology-
dc.subject.MESHErbB Receptors / genetics-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHLung Neoplasms* / genetics-
dc.subject.MESHLung Neoplasms* / pathology-
dc.subject.MESHMutation / genetics-
dc.subject.MESHProtein Kinase Inhibitors / pharmacology-
dc.titleLazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHyunwook Kim-
dc.contributor.googleauthorBeung-Chul Ahn-
dc.contributor.googleauthorJiyun Lee-
dc.contributor.googleauthorJii Bum Lee-
dc.contributor.googleauthorMin-Hee Hong-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorSun Min Lim-
dc.identifier.doi10.1016/j.lungcan.2023.107213-
dc.contributor.localIdA01126-
dc.contributor.localIdA01166-
dc.contributor.localIdA05930-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.contributor.localIdA04393-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid37104879-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0169500223007511-
dc.subject.keywordLazertinib-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordReal-world data-
dc.subject.keywordT790M EGFR mutation-
dc.contributor.alternativeNameKim, Hyun Wook-
dc.contributor.affiliatedAuthor김현욱-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor이기쁨-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor홍민희-
dc.citation.volume180-
dc.citation.startPage107213-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.180 : 107213, 2023-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.